Back

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy

  • Clinical Trial Information

    Trial Contact: El-Shami, Jessica; Cevallos, Claudia; Leffin, Melissa; Spinelli, Jennifer

  • IRB No: AALL1732

    Protocol Abbrev: AALL1732

    Principal Investigator: Amy A Smith, MD

    Phase: Drug: Phase III

    Age Group: Adult;Pediatric

    Secondary Protocol No: AALL1732

    Treatment: Drug: Cyclophosphamide, Drug: Cytarabine, Drug: Daunorubicin, Drug: Daunorubicin Hydrochloride, Drug: Dexamethasone, Drug: Doxorubicin, Drug: Doxorubicin Hydrochloride, Biological: Inotuzumab Ozogamicin, Drug: Leucovorin, Drug: Leucovorin Calcium, Drug: Mercaptopurine, Drug: Methotrexate, Drug: Pegaspargase, Drug: Prednisolone, Radiation: Radiation Therapy, Drug: Thioguanine, Drug: Vincristine, Drug: Vincristine Sulfate

    Therapies Involved: Chemotherapy

    ClinicalTrials.gov ID: NCT03959085

  • Objective

    To determine in a randomized manner if the addition of 2 blocks of inotuzumab ozogamicin to modified Berlin-Frankfurt-Munster (mBFM) chemotherapy will improve 5-year disease-free survival (DFS) in children and young adults with high-risk B-cell acute lymphoblastic leukemia (HR B-ALL).

  • Key Eligibility

    •  B-ALL and MPAL patients must be enrolled on APEC14B1 and consented to eligibility studies (Part A) prior to treatment and enrollment on AALL1732. Note that central confirmation of MPAL diagnosis must occur within 7 business days after enrollment for MPAL patients. If not performed within this time frame, patients will be taken off protocol.
    •  APEC14B1 is not a requirement for B-LLy patients but for institutional compliance every patient should be offered participation in APEC14B1. B LLy patients may directly enroll on AALL1732 and MUST submit eligibility studies as outlined.

    •  White blood cell count (WBC) criteria for patients with B-ALL (within 7 days prior to the start of protocol-directed systemic therapy):
    ◦Age 1-9.99 years: WBC >= 50,000/uL
    ◦Age 10-24.99 years: Any WBC

    ◦Age 1-9.99 years: WBC < 50,000/uL with:
    ◾Testicular leukemia
    ◾CNS leukemia (CNS3)
    ◾Steroid pretreatment.



    •  White blood cell count (WBC) criteria for patients with MPAL (within 7 days prior to the start of protocol-directed systemic therapy):
    ◦Age 1-24.99 years: any WBC.


    •  Patient has newly diagnosed B-ALL or MPAL (by World Health Organization [WHO] 2016 criteria) with > 25% blasts on a bone marrow (BM) aspirate;
    ◦OR If a BM aspirate is not obtained or is not diagnostic of acute leukemia, the diagnosis can be established by a pathologic diagnosis of acute leukemia on a BM biopsy;
    ◦OR A complete blood count (CBC) documenting the presence of at least 1,000/uL circulating leukemic cells if a bone marrow aspirate or biopsy cannot be performed.

    •  Patient has newly diagnosed B-LLy Murphy stages III or IV.
    •  Patient has newly diagnosed B-LLy Murphy stages I or II with steroid pretreatment.
    •  Note: For B-LLy patients with tissue available for flow cytometry, the criterion for diagnosis should be analogous to B-ALL. For tissue processed by other means (i.e., paraffin blocks), the methodology and criteria for immunophenotypic analysis to establish the diagnosis of B-LLy defined by the submitting institution will be accepted.